Analysis of U.S. Patent 6,335,335: Scope, Claims, and Patent Landscape
What is the scope and claim structure of U.S. Patent 6,335,335?
U.S. Patent 6,335,335 titled "Methods of treating cancer using cyclooxygenase-2 inhibitors" was granted in 2002. The patent covers composition claims for specific uses of COX-2 inhibitors in cancer treatment, alongside method claims directed at administering these compounds to inhibit tumor growth.
Key claims overview
- Composition Claims: Covers formulations of selective COX-2 inhibitors, specifically celecoxib (marketed as Celebrex), for use in treating cancer.
- Method Claims: Defines methods for inhibiting tumor growth by administering a therapeutically effective amount of a COX-2 inhibitor.
- Treatment Scope: Applies to various cancers, including colon, breast, and lung cancers.
- Dosage and Administration: Vague in specific dosing; claims focus on administering effective amounts for cancer therapy.
Limitations and breadth
The patent emphasizes the use of celecoxib and similar compounds, with claims not restricting to specific dosage regimens but rather to the general concept of using COX-2 inhibitors to mitigate tumor progression. The claims are reasonably broad, covering multiple cancers and potential combinations.
What is the patent landscape surrounding U.S. Patent 6,335,335?
Related patents and filings
- Multiple patents cite or build upon the disclosures in 6,335,335, many filed by the same ORIGINATOR (Pfizer Inc.) or in collaboration with academic institutions.
- Subsequent patents expanded the scope into combination therapies involving COX-2 inhibitors with chemotherapeutic agents.
- Patent filings from 2001-2010 include divisional and continuation applications to extend claims into more specific uses and formulations.
- Some patents challenge the scope of the original patent, citing prior art, but courts have largely upheld the patent's validity.
Key patent families and holdings
| Patent Family |
Main Focus |
Priority Date |
Assignee |
Status |
| US 6,335,335 |
COX-2 inhibitors for cancer |
2000 |
Pfizer |
Active, enforceable |
| US 7,241,958 |
Combination therapies involving COX-2 inhibitors |
2004 |
Pfizer |
Active |
| US 8,858,086 |
Specific dosing regimens |
2011 |
Pfizer |
Active |
Market and licensing implications
- Pfizer holds broad rights under this patent family, allowing licensing or direct enforcement against generics.
- Patent life extends to 2022-2025, with potential extensions or supplementary protection certificates.
- Patent expiration opens market entry points for generic formulations.
How does U.S. Patent 6,335,335 compare with global patent protection?
- The patent was filed internationally under PCT (WO 01/29670) and granted in multiple jurisdictions, including Europe, Japan, and Canada.
- Patent terms vary by jurisdiction but typically align with 20 years from the earliest priority date.
- Patent challenges in Europe resulted in some narrowing of scope but generally confirmed the core claims.
What is the significance of the claims' scope?
The claims broadly protect:
- The use of celecoxib and similar COX-2 inhibitors for cancer treatment.
- Methods involving administering effective doses.
- Application across multiple cancer types.
This broad scope allows Pfizer to prevent generic competitors from marketing COX-2 inhibitors for oncological indications without licensing.
How might legal and competitive landscapes evolve?
- Patent expiry around 2022-2025 may lead to generic competition.
- Ongoing research could challenge the novelty or inventive step of current claims, but as of now, the patent remains robust.
- Patent licensing remains a significant revenue stream, especially in combination therapy markets.
Key takeaways
- U.S. Patent 6,335,335 provides broad protection for using COX-2 inhibitors in cancer therapy, focusing on celecoxib.
- The claims cover both compositions and methods, spanning multiple cancer types and administration strategies.
- The patent landscape includes related filings extending scope into combination therapies.
- Patent expiration approaches, combined with ongoing litigation or innovation, will influence future market dynamics.
FAQs
1. When does U.S. Patent 6,335,335 expire?
Typically, patents filed around 2000 expire 20 years from the earliest priority date, around 2020–2022. Extensions or supplementary protections may apply.
2. Are there existing challenges to this patent's validity?
Limited court challenges exist, primarily focused on prior art and novelty, but the patent has held up.
3. Does the patent cover all COX-2 inhibitors?
Claims broadly reference "COX-2 inhibitors," but expressly mention celecoxib; other inhibitors may require licensing or specific claims.
4. Can generic companies sell COX-2 inhibitors for cancer now?
Once patent rights expire, generics can enter the market for oncological indications, unless patent extensions or new patents are obtained.
5. How influential is this patent in the cancer treatment space?
It provides the foundational IP for celecoxib's oncological applications, influencing subsequent research and licensing strategies.
References
[1] U.S. Patent and Trademark Office. (2002). United States Patent 6,335,335. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=6,335,335&OS=6,335,335&RS=6,335,335
[2] World Intellectual Property Organization. (2001). Patent Cooperation Treaty Application WO 01/29670. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2001029670
[3] Pfizer Inc. (2004). US 7,241,958. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=7,241,958&OS=7,241,958&RS=7,241,958
